Celcuity Inc. (CELC) is held by 5 of 149 tracked super-investor funds (144 filed in Q2) in 2026 Q2 13F filings, with 3 funds adding and 3 funds trimming or exiting versus the previous quarter. Latest close $55.60 as of Nov 18, 2026.
Data as of Nov 18, 2026 (prices) · 2026 Q2 13F filings (quarter ended Jun 30, 2026) · Latest Form 4: none in the last 90 days · Congress to Nov 16, 2026.
Perceptive Advisors · Baker Bros. Advisors · Avoro Capital Advisors — 5 tracked funds hold CELC. See all holders.
No insider open-market activity or Congress trades reported for this stock in the recent window. Insider trading · Politician trading.
AVALYN PHARMA INC (AVLN) · Beta Bionics, Inc. (BBNX) · IDEAYA BIOSCIENCES INC (IDYA) · Immatics N.V. (IMTX) · KYMERA THERAPEUTICS INC (KYMR) — stocks the same funds also hold. See all related stocks.
| Fund | Portfolio weight | Shares | Change vs prev. quarter |
|---|---|---|---|
| Perceptive Advisors | 5.02% | 3,197,200 | ADDED (+2.2%) Q3 filed Nov 16 |
| Baker Bros. Advisors | 4.15% | 7,915,792 | HELD Q3 filed Nov 16 |
| Avoro Capital Advisors | 3.19% | 3,400,000 | ADDED (+0.7%) Q3 filed Nov 16 |
| RTW Investments | 2.95% | 3,304,903 | ADDED (+8.7%) Q3 filed Nov 16 |
| Deerfield Management | 1.58% | 1,451,014 | TRIMMED (-15.3%) Q3 filed Nov 16 |
| Polen Capital Management | — | — | EXITED |
| Avoro Capital Advisors | — | — | EXITED |
Source: SEC Form 13F filings, quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. Fund counts aggregate every share class mapped to this ticker.
Price change since quarter-end: -44.5% from the close on the first trading day after the quarter ended (Jul 1, 2026) to the latest close (Nov 17, 2026). 13F does not report purchase prices — this is the price change since the quarter-end close, not a gain on any fund’s actual purchase.
Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.
Closing prices (unadjusted for dividends), last 2 years — 501 trading days to Nov 18, 2026. Dashed lines mark 13F filing deadlines. Source: Yahoo Finance daily bars.
| Institutions holding | 279 of 8,857 filers |
| Long-only filers among them | 274 |
| Change vs 2026 Q1 | +8 net · 273 entered · 265 exited |
| Shares reported, all filers | 56,798,764 |
| Reported value, all filers | $6.0B |
Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).
| Exchange | Nasdaq |
| Industry | Services-Medical Laboratories (SIC 8071) |
| Net income · FY2025 | $-177.0M |
| Total assets · FY2025 | $466.6M |
| Shares outstanding | 48,931,908 |
| Market cap (at latest close) | $2.7B |
Source: SEC EDGAR company filings (submissions and company facts), collected Oct 30, 2026. Shares outstanding as reported Aug 5, 2026.
| Shares short · Oct 15, 2026 | 10,252,223 |
| Share of shares outstanding | 20.95% |
| Days to cover | 5.76 |
Shares short at recent settlements — Jul 31, 2026: 10.3M · Aug 14, 2026: 10.5M · Aug 31, 2026: 10.7M · Sep 15, 2026: 11.4M · Sep 30, 2026: 11.0M · Oct 15, 2026: 10.3M.
Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of Aug 5, 2026.
Data unavailable — no Form 4 transactions for this ticker were parsed in the last 90 days.
| Filed | Form | Price change since disclosure |
|---|---|---|
| Jul 16, 2026 | SCHEDULE 13D/A | -34.4% (close Jul 17, 2026 → Nov 17, 2026) |
Reference close is the first trading day after the filing (Jul 17, 2026). A Schedule 13D reports beneficial ownership, not a purchase — there is no transaction price to show. Source: SEC EDGAR Schedule 13D filings.
| Filed | Filer | Form | Shares | % owned | Event date | Source |
|---|---|---|---|---|---|---|
| Aug 11, 2026 | BANK OF AMERICA CORP /DE/ | SC 13G | 3,170,198 | 6.5% | Jun 30, 2026 | SEC filing |
| Jul 16, 2026 | Baker Bros. Advisors LP | SC 13G | 4,877,963 | 10.0% | Jul 14, 2026 | SEC filing |
| Jul 16, 2026 | Baker Bros. Advisors LP | SC 13D/A | 4,877,963 | 10.0% | Jul 14, 2026 | SEC filing |
| May 15, 2026 | RTW Investments, LP | SC 13G | 3,039,621 | 6.3% | Mar 31, 2026 | SEC filing |
| Mar 24, 2026 | Baker Bros. Advisors LP | SC 13D/A | 9,582,874 | 20.0% | Mar 20, 2026 | SEC filing |
| Mar 9, 2026 | Growth Equity Opportunities 18 VGE, LLC | SC 13D/A | 2,285,561 | 4.9% | Mar 5, 2026 | SEC filing |
| Feb 17, 2026 | Perceptive Advisors LLC | SC 13G/A | 3,160,200 | 6.8% | Dec 31, 2025 | SEC filing |
| Feb 17, 2026 | Avoro Capital Advisors LLC | SC 13G | 3,111,111 | 6.7% | Dec 31, 2025 | SEC filing |
| Feb 12, 2026 | Soleus Private Equity Fund II, L.P. | SC 13G/A | 142,118 | 0.3% | Dec 31, 2025 | SEC filing |
| Jan 16, 2026 | Growth Equity Opportunities 18 VGE, LLC | SC 13D/A | 2,910,561 | 6.3% | Jan 14, 2026 | SEC filing |
One filing is one row; a filing may list several reporters and the first is shown. Figures are as filed, including amendments that report zero shares after a transfer. Source: SEC Schedule 13D/G filings, 57,443 filings parsed to Oct 2, 2026.
Data unavailable — no congressional STOCK Act transactions for this ticker were parsed in the current window (as of Nov 16, 2026).
Red Flags
· Distress Risk (Altman Z″) — Altman Z″-Score below 1.10
Key figures
· Distress Risk (Altman Z″) — Z″-Score: 0.60 · Working capital / assets: 0.90 · Retained earnings / assets: -0.96 · EBIT / assets: -0.37 · Equity / liabilities: 0.27
Financial screens are computed from SEC company financial statements; red-flag models are screens, not verdicts — see Methodology.
Also held by the tracked funds that hold CELC — ranked by lift, the co-holding pattern described in Methodology: AVALYN PHARMA INC (AVLN) · Beta Bionics, Inc. (BBNX) · IDEAYA BIOSCIENCES INC (IDYA) · Immatics N.V. (IMTX) · KYMERA THERAPEUTICS INC (KYMR) · MADRIGAL PHARMACEUTICALS INC (MDGL) · STOKE THERAPEUTICS INC (STOK) · AVALO THERAPEUTICS INC (AVTX).
| Filed | Items | Source |
|---|---|---|
| Nov 5, 2026 | 2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits | SEC filing |
| Oct 2, 2026 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits | SEC filing |
| Sep 30, 2026 | 7.01 Regulation FD Disclosure · 8.01 Other Events · 9.01 Financial Statements and Exhibits | SEC filing |
Source: SEC EDGAR Form 8-K filings, latest first. Amendments (Form 8-K/A) are labeled as such. Item labels are the SEC's item titles; a filing can carry several items. Item 5.02 covers both departures and appointments, which this index does not distinguish.
AVALYN PHARMA INC (AVLN) · Track Record: how the signals scored · Practice timing on CELC
One email a week: the week’s new filings and research. Subscribe free
Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.